Mavefund EN
Compass Pathways Plc logo

Compass Pathways Plc

CMPS
Letzter Kurs (USD) US$13.64
Marktkapitalisierung (USD) US$1.8b
Kursänderung 12 Monate 208.60%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Universal Health Services IncUHS Vergleich DaVita HealthCare Partners IncDVA Vergleich CHEMED CORPCHE Vergleich Zoetis IncZTS Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Compass Pathways Plc Überblick

Branche: Medical Care Facilities

Sektor: Healthcare

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatmen

Research-Überblick

Letztes Berichtsdatum 2026-08-05

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Compass Pathways Plc (CMPS): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
CMPS · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Medical Care Facilities
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-05
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Compass Pathways Plc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 05, 2026

Quarterly result summary

Net loss was -$253.8M. R&D expense was $29.2M.

Net loss -$253.8M reported
R&D expense $29.2M reported
G&A expense $23.2M reported
Cash $433.3M reported

Was sich verändert hat

  • Review the source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing 10-Q Aug 05, 2026 SEC filing 8-K Aug 05, 2026 SEC filing 8-K May 13, 2026 Earnings release Earnings release May 13, 2026 SEC filing 10-Q May 13, 2026 SEC filing 10-K Mar 24, 2026 SEC filing 8-K Mar 24, 2026 Earnings release Earnings release Mar 24, 2026 SEC filing 10-Q Nov 04, 2025 SEC filing 8-K Nov 04, 2025 Earnings release Earnings release Nov 04, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 2.00/5
Compass Pathways Plc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

Eigenkapitalrendite

Score 0.27/5
Compass Pathways Plc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Compass Path... CMPS US$1.8b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 2.21/5
Compass Pathways Plc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Compass Path... CMPS US$1.8b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

Verschuldung

Score 3.63/5
Compass Pathways Plc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Compass Path... CMPS US$1.8b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Compass Pathways Plc logo

Compass Pathways Plc

US$13.64

US$1.8b

-3.88%

208.60%